Technical Analysis for COCP - Cocrystal Pharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 4.42% | |
Wide Bands | Range Expansion | 4.42% | |
Gapped Down | Weakness | 4.42% | |
Calm After Storm | Range Contraction | 4.42% | |
Wide Bands | Range Expansion | 4.42% | |
Upper Bollinger Band Touch | Strength | 4.42% | |
Down 3 Days in a Row | Weakness | 4.42% | |
Calm After Storm | Range Contraction | 3.92% | |
Wide Bands | Range Expansion | 3.92% | |
Upper Bollinger Band Touch | Strength | 3.92% |
Alert | Time |
---|---|
Upper Bollinger Band Resistance | about 4 hours ago |
Gap Down Partially Closed | about 4 hours ago |
Gap Down Closed | about 4 hours ago |
Reversed from Down | about 4 hours ago |
2x Volume Pace | about 4 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/11/2024
Cocrystal Pharma, Inc. Description
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Coronavirus Influenza Viruses Microbiology Virus Antiviral Drug Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.1 |
52 Week Low | 1.325 |
Average Volume | 19,497 |
200-Day Moving Average | 1.85 |
50-Day Moving Average | 1.84 |
20-Day Moving Average | 1.87 |
10-Day Moving Average | 1.93 |
Average True Range | 0.18 |
RSI (14) | 58.68 |
ADX | 31.02 |
+DI | 32.67 |
-DI | 14.14 |
Chandelier Exit (Long, 3 ATRs) | 1.91 |
Chandelier Exit (Short, 3 ATRs) | 2.19 |
Upper Bollinger Bands | 2.17 |
Lower Bollinger Band | 1.58 |
Percent B (%b) | 0.81 |
BandWidth | 31.69 |
MACD Line | 0.06 |
MACD Signal Line | 0.02 |
MACD Histogram | 0.0319 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.30 | ||||
Resistance 3 (R3) | 2.30 | 2.23 | 2.26 | ||
Resistance 2 (R2) | 2.23 | 2.17 | 2.22 | 2.25 | |
Resistance 1 (R1) | 2.14 | 2.13 | 2.18 | 2.14 | 2.23 |
Pivot Point | 2.07 | 2.07 | 2.09 | 2.06 | 2.07 |
Support 1 (S1) | 1.98 | 2.01 | 2.03 | 1.98 | 1.89 |
Support 2 (S2) | 1.91 | 1.97 | 1.91 | 1.87 | |
Support 3 (S3) | 1.82 | 1.91 | 1.86 | ||
Support 4 (S4) | 1.82 |